Loading clinical trials...
Loading clinical trials...
Current therapies for Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Burzynski Research Institute
NCT04496349 · T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma
NCT00923442 · Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS), and more
NCT04188678 · Leukemia, Lymphoma, and more
NCT00179673 · Non-Hodgkins Lymphoma
NCT00574730 · Non-Hodgkins Lymphoma
Burzynski Clinic
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions